What Is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of endogenous human GHRH with a stabilizing trans-3-hexenoic acid group attached to the N-terminus. It stimulates the pituitary gland to produce and secrete endogenous growth hormone through natural pulsatile patterns, distinguishing it mechanistically from exogenous GH administration.
Tesamorelin holds a significant distinction among research peptides: it is one of the very few GHRH analogues to have received full FDA approval. It was approved in 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This regulatory history provides researchers with an unusually comprehensive and rigorously validated clinical dataset that most peptide compounds lack entirely.
Tesamorelin Mechanism of Action
Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile secretion of endogenous growth hormone. Its key mechanistic features in research contexts:
- Pulsatile GH secretion: Unlike direct GH administration, tesamorelin preserves physiological GH pulse patterns, maintaining negative feedback regulation through somatostatin and IGF-1
- Visceral fat mobilization: Elevated GH stimulates lipolysis preferentially in visceral adipose tissue via hormone-sensitive lipase activation
- IGF-1 elevation: GH-induced hepatic IGF-1 production mediates downstream anabolic and metabolic effects studied in multiple research contexts
- Hepatic fat reduction: Research has documented significant reductions in intrahepatic lipid content, relevant to NAFLD/MASH model research
Tesamorelin Research Data
The clinical research base for tesamorelin is one of the most robust available for any GHRH analogue:
- Lipodystrophy (FDA approval trials): Phase 3 trials demonstrated a 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks in HIV-associated lipodystrophy patients, with concomitant improvements in lipid profiles and trunk-to-limb fat ratios
- Cognitive function (2021 RCT): A randomized controlled trial published in Nature Communications found tesamorelin significantly improved verbal memory and executive function in older adults (65+) with mild cognitive impairment over 20 weeks, compared to placebo — the first GHRH analogue to demonstrate cognitive improvement in a controlled trial
- NAFLD research: A published RCT demonstrated tesamorelin reduced intrahepatic lipid content by approximately 18% over 12 months in HIV-infected patients with NAFLD, compared to no significant change in placebo, alongside reductions in liver enzymes
- Body composition: Multiple studies confirm tesamorelin reduces trunk fat, improves lean body mass ratios, and favorably affects lipid profiles without significant changes in fasting glucose
Tesamorelin Dosage Reference
| Research Context | Dose (Published Trials) | Duration |
|---|---|---|
| Lipodystrophy (FDA approval) | 2mg/day subcutaneous | 26–52 weeks |
| Cognitive function RCT (2021) | 1mg/day subcutaneous | 20 weeks |
| NAFLD research protocol | 2mg/day subcutaneous | 52 weeks |
| Body composition studies | 1–2mg/day subcutaneous | 12–26 weeks |
Dosage data from published peer-reviewed clinical trials. Provided for research reference only. Not dosing guidance for human use.
Side Effects from Trial Data
Tesamorelin’s adverse event profile from FDA approval and post-approval trials:
- Injection site reactions — most common (redness, bruising, pain)
- Peripheral edema — dose-dependent, attributed to GH-mediated fluid retention
- Arthralgia and myalgia at higher doses
- Transient increases in fasting glucose in some subjects
- Carpal tunnel syndrome reported in a subset of long-term users in observational data
Tesamorelin vs. Sermorelin — GHRH Analogue Research Comparison
| Parameter | Tesamorelin | Sermorelin |
|---|---|---|
| Sequence | Full GHRH (1-44) + stabilizer | GHRH fragment (1-29) |
| Half-life | ~26 minutes | ~10–20 minutes |
| FDA approval | Yes (Egrifta — lipodystrophy) | Previously approved, withdrawn 2008 |
| Clinical data depth | Extensive Phase 3 + post-marketing | Limited older data |
| Cognitive research | Published RCT showing benefit | No controlled human data |
Where to Buy Tesamorelin for Research
Given tesamorelin’s clinical pedigree, researchers require material that meets the purity standards used in the trials that established its profile. Key supplier criteria:
- HPLC purity ≥99% with batch-specific documentation
- MS/MS identity verification confirming full 44-amino acid sequence
- Independent third-party COA
- Lyophilized format with proper cold chain handling
Core Power Peptides supplies Tesamorelin 10mg and 20mg vials at ≥99% purity, HPLC and MS/MS verified per batch, with third-party COA on request.
Research Disclaimer: All information on this page is for educational and scientific reference purposes only. Tesamorelin (Egrifta) is approved only for HIV-associated lipodystrophy. All other applications described here are investigational research contexts only. This product is sold strictly for in vitro research and laboratory use. Not for human consumption. Not medical advice.